| Project/Area Number |
16H07099
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
Aoki Miho 福島県立医科大学, 公私立大学の部局等, 助手 (10783227)
|
|---|
| Research Collaborator |
OGAWA Kazuma 金沢大学, 新学術創成研究機構, 准教授 (30347471)
|
|---|
| Project Period (FY) |
2016-08-26 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | ペプチド / GRP受容体 / 癌 / 内用放射線治療 / 放射線 / 分析科学 / 放射性薬剤 / α線 / 前立腺がん / 放射線、Ｘ線、粒子線 / 核医学 / 加速器 |
|---|
| Outline of Final Research Achievements |
[18F]FDG is useful for cancer diagnosis, but it is difficult to accurately diagnose for prostate cancer due to its low accumulation. Therefore, development of alternative diagnosic agents is desired. Human gastrin releasing peptide receptor (GRPR) has been reported to be overexpressed in various cancers including prostate cancer. I aimed to develop agents for the diagnosis and treatment of prostate cancer by labeling derivatives of Bombesin (BNN), which is a ligand for GRPR, with radioactive halogens including iodene-125 and astatine-211.
|
